Key statistics
On Monday, Regeneron Pharmaceuticals Inc (REGN:VIE) closed at 913.00, -16.35% below its 52-week high of 1,091.50, set on Aug 29, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 922.60 |
---|---|
High | 923.60 |
Low | 913.00 |
Bid | 907.60 |
Offer | 914.20 |
Previous close | 924.80 |
Average volume | 0.60 |
---|---|
Shares outstanding | 110.23m |
Free float | 107.33m |
P/E (TTM) | 26.82 |
Market cap | 111.65bn USD |
EPS (TTM) | 37.77 USD |
Data delayed at least 15 minutes, as of Oct 07 2024.
More ▼
- Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD
- Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)
- Regeneron to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on October 31, 2024
- Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old
- Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
- EYLEA HD® (aflibercept) Injection 8 mg Data at EURETINA Reinforce Long-term Durability, Sustained Fluid Control and Safety Profile
- Dupixent® (dupilumab) Phase 3 Trial Confirms Significant Improvements in Itch and Hives for Patients with Chronic Spontaneous Urticaria (CSU)
- Dupixent® (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial
- Libtayo® (cemiplimab) Demonstrates Durable Survival Benefit at Five Years in Advanced Non-small Cell Lung Cancer
- Regeneron to Highlight Progress Across Its Differentiated Oncology Portfolio and Pipeline at WCLC and ESMO
More ▼